All In Biotech

Drug Trial Radar · NCT04771273

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.

Last checked: Nov 19, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 295 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

295

Actual

Start

Apr 27, 2021

Primary completion

Nov 9, 2023

Study completion Dec 21, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The study tests 3 different doses of BI 456906 to find the dose that helps best. Participants are put into 4 groups randomly, which means by chance. There are 3 groups that each receive a different dose of BI 456906 and there is 1 group that receives placebo. BI 456906 and placebo are given as an injection under the skin once per week. The placebo injection looks like the BI 456906 injection but does not contain any medicine. Participants are in the study for a little over 1 year (60 weeks). During this time, they visit the study site several times and have some video calls in addition. At the visits, the study doctors take different measurements. To see whether the treatment works, the doctors take a very small sample of liver tissue (biopsy) from each participant at the start and at the end of the study. They also examine the liver by ultrasound and MRI. The doctors also regularly check the general health of the participants.

Conditions

  • Non-alcoholic Steatohepatitis (NASH)

Interventions

  • SurvodutideDrug

    Survodutide

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance TreatmentTime frame: At baseline and at 48 weeks.
  2. Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance TreatmentTime frame: At baseline and after 48 weeks of treatment.

Locations

154 sites in 25 countries. Site status is shown where the registry gives one.

  • North Alabama Health Research, LLC

    Huntsville, Alabama

  • Southern California Research Center

    Coronado, California

  • Velocity Clinical Research

    Huntington Park, California

  • Velocity Clinical Research

    Panorama City, California

  • Quest Clinical Research

    San Francisco, California

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Integrity Clinical Research, LLC

    Doral, Florida

  • Covenant Metabolic Specialists, LLC

    Fort Myers, Florida

  • Optimus U Corporation

    Miami, Florida

  • Sanchez Clinical Research ,Inc

    Miami, Florida

  • Ocala GI Research

    Ocala, Florida

  • Omega Research Orlando, LLC

    Orlando, Florida

  • Covenant Metabolic Specialists, LLC

    Sarasota, Florida

  • Gastrointestinal Specialists of Georgia

    Marietta, Georgia

  • Digestive Research Alliance of Michiana

    South Bend, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Delta Research Partners, LLC

    Bastrop, Louisiana

  • Centex Studies, Inc.

    Lake Charles, Louisiana

  • Tandem Clinical Research

    Marrero, Louisiana

  • NECCR PrimaCare Research, LLC

    Fall River, Massachusetts

  • National Diabetes and Obesity Research Institute

    Biloxi, Mississippi

  • Gastrointestinal Associates

    Flowood, Mississippi

  • AIG Digestive Disease Research

    Florham Park, New Jersey

  • Northeast GI Research Division

    Concord, North Carolina

  • Lucas Research, Inc.

    Morehead City, North Carolina

  • Digestive Diseases Research Center

    Greenwood, South Carolina

  • Palmetto Clinical Research

    Summerville, South Carolina

  • Digestive Health Research, LLC

    Hermitage, Tennessee

  • Texas Clinical Research Institute, LLC

    Arlington, Texas

  • Texas Liver Institute

    Austin, Texas

  • South Texas Research Institute

    Brownsville, Texas

  • South Texas Research Institute

    Edinburg, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • American Research Corporation at the Texas Liver Institute

    San Antonio, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Medical University of Graz State Hospital - University Hospital Graz

    Graz, Austria

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.